Journal of Clinical Oncology, Vol 15, 1309-1317, Copyright © 1997 by American Society of Clinical Oncology
High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients
PJ Stiff, R Bayer, C Kerger, RK Potkul, D Malhotra, DJ Peace, D Smith and SG Fisher
Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.
PURPOSE: To examine the prognostic factors associated with prolonged
progression-free survival (PFS) and overall survival (OS) in 100
consecutively treated women undergoing autologous stem-cell transplant for
advanced ovarian cancer. PATIENTS AND METHODS: From October 1989 to
February 1996, we transplanted 100 patients with ovarian cancer following
chemotherapy with high-dose carboplatin, mitoxantrone, and cyclophosphamide
with or without cyclosporine (n = 70); melphalan and mitoxantrone with or
without paclitaxel (n = 25); or other regimens (n = 5). Their median age
was 48 years (range, 23 to 65), 70% had papillary serous histology, 72% had
grade III tumors, 66% were platinum- resistant, and 61% had > or = 1 cm
bulk. The median number of prior regimens was two (range, one to six).
Univariate and multivariate analyses were performed to examine age (< v
> or = mean), stage, initial bulk, histology, grade, response to initial
therapy, number of prior regimens, time from diagnosis to transplant,
transplant regimen, platinum sensitivity, and bulk (< v > or = 1 cm)
at transplant. RESULTS: The median PFS and OS times for the 100 patients
were 7 and 13 months. A stepwise Cox proportional hazards model identified
tumor bulk (P = .0001), and cisplatin sensitivity (P = .0249) as the best
predictors of PFS. Age (P = .0017), bulk at transplant (P = .0175), and
platinum sensitivity (P = .0330) provided the best prediction of OS. The
median PFS and OS times for the 20 patients with platinum- sensitive, <
or = 1-cm disease were 19 and 30 months. No differences in OS were seen
when chemotherapy or surgery was used to achieve a minimal disease state.
CONCLUSION: Before consideration of high-dose therapy for
recurrent/persistent advanced ovarian cancer, patients should undergo
debulking surgery or chemotherapy to achieve a minimal disease state.
Patients with platinum-resistant, bulky disease should not be transplanted.
The optimal patients for this therapy may be those with minimal disease
responsive to initial chemotherapy.
This article has been cited by other articles:
|
|
|
|
 
R. F. Ozols
Ovarian Cancer: Is Dose Intensity Dead?
J. Clin. Oncol.,
September 20, 2007;
25(27):
4157 - 4158.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al.
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
Ann. Onc.,
October 1, 2006;
17(10):
1479 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Navo and J. A. Smith
Update on the Prevention and Treatment of Ovarian Cancer
Journal of Pharmacy Practice,
June 1, 2003;
16(3):
149 - 156.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Bookman
Developmental Chemotherapy and Management of Recurrent Ovarian Cancer
J. Clin. Oncol.,
May 15, 2003;
21(90100):
149s - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Scheulen, R. A. Hilger, C. Oberhoff, J. Casper, M. Freund, K. M. Josten, M. Bornhauser, G. Ehninger, W. E. Berdel, J. Baumgart, et al.
Clinical Phase I Dose Escalation and Pharmacokinetic Study of High-Dose Chemotherapy with Treosulfan and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Advanced Malignancies
Clin. Cancer Res.,
November 1, 2000;
6(11):
4209 - 4216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Stiff, J. Veum-Stone, H. M. Lazarus, L. Ayash, J. R. Edwards, A. Keating, J. P. Klein, D. J. Oblon, T. C. Shea, S. Thome, et al.
High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report
Ann Intern Med,
October 3, 2000;
133(7):
504 - 515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes
High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer
Oncologist,
February 1, 2000;
5(1):
1 - 13.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Markman and M. A. Bookman
Second-Line Treatment of Ovarian Cancer
Oncologist,
February 1, 2000;
5(1):
26 - 35.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Makatsoris and M. V. Seiden
High-Dose Therapy for Ovarian Carcinoma
Oncologist,
October 1, 1997;
2(5):
330 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
